Dr. Coleman, a member of the Alliance’s Scientific and Medical Advisory Board, conducted an interview on ovarian cancer therapies for the Cancer Network. He discussed the heterogeneity of ovarian cancer, angiogenesis inhibitors and new drugs in the pipeline. The full interview can be found here
Research published online last week in Nature Communications suggests that some of the cell lines most frequently used to study high-grade serous ovarian cancer (HGSOC) may not be the best. OCRF grantee and SAC member Douglas Levine, MD was one of the authors of the paper. Cell lines derived from tumor tissue are the most … Continued
In an article published last week in The Lancet, an international group of investigators examined whether ovarian cancer tumors’ expression of the progesterone receptor (PR) and estrogen receptor (ER) was associated with survival in various subtypes of ovarian cancer. To date, few biomarkers of ovarian cancer prognosis have been established. The study, which included 2,933 women, … Continued
Women with a family history of breast cancer but no BRCA1/2 mutation were found to be at average risk for developing ovarian cancer. The prospective study of 8005 women from a breast cancer family history clinic found that women with a BRCA2 mutation had a 17-times higher risk of developing ovarian cancer than average, and … Continued
In an interview, 3-time grantee Dr. Zhang discusses his research and what it means to receive an award from OCRF.
We recently returned from the annual meeting of the American Society of Clinical Oncology (ASCO), an annual event that gathers thousands of cancer researchers from around the world. Many new studies on or related to ovarian cancer were presented at this year’s ASCO meeting. Click here to read a summary of ovarian cancer research from … Continued
In a unanimous ruling issued June 13, 2013, the US Supreme Court ruled that private companies do not have the right to patent human genes. In Association for Molecular Pathology et al. v. Myriad Genetics, the court considered the validity of patents held by the Utah-based company Myriad Genetics for the BRCA1 and BRCA2 genes, which … Continued
Society for Nuclear Medicine and Molecular Imaging (SNMMI) Advocate Report from Laurel Pracht As a member of the SNMMI Advocate Advisory Board, formed in 2010 to better bridge the gap between the patient and nuclear medicine communities, I represent the ovarian patient community. Other diseases, including cancer, brain and heart disease are represented as well. … Continued
Ruling Will Give Women More Options to Learn About Genetic Risk Washington, DC—The Supreme Court ruled today that a company cannot patent naturally occurring genes, including isolated gene segments, overturning a decision made by the United States Court of Appeals for the Federal Circuit in August 2012, which upheld a patent claim on the BRCA1 … Continued
A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use. See the abstract here
In research presented at the American Society of Clinical Oncology meeting this week, researchers found that shortening the break between chemotherapy sessions improved quality of life for patients, without negatively impacting efficacy. Results from a randomized, phase III trial of over 800 women conducted in Italy showed that lower-dose weekly carboplatin plus paclitaxel was associated … Continued
Research presented at the American Society of Clinical Oncology annual meeting this week suggests that adding the drug pazopanib (trade name Votrient) to standard treatment extends progression-free survival in ovarian cancer patients by 5.6 months. Pazopanib is an oral anti-angiogenesis drug already approved to treat kidney cancer. The phase III study of over 900 women … Continued
Get email updates about research news, action alerts, and ways to join the fight.
